Award details

Improving the quality of FMD vaccines by addition of novel adjuvants to stimulate mixed Th1 and Th2 responses

Reference	BBS/E/I/00001846
Principal Investigator / Supervisor	Professor Satya Parida
Co-Investigators / Co-Supervisors	Dr Geraldine Taylor
Institution	The Pirbright Institute
Department	The Pirbright Institute Department
Funding type	Research
Value (£)	14,620
Status	Completed
Type	Institute Project
Start date	20/05/2013
End date	06/01/2014
Duration	8 months

Abstract

Current oil adjuvanted FMD vaccines induce variable T cell responses, whilst novel adjuvants can prime greater and more consistent T cell and humoral responses that may give longer-duration of protection. Our recent published data demonstrate a positive correlation between IFNgamma production by stimulated CD4+ T cells and protection in vaccinated cattle.The hypotheses underlying the proposed research are that there is a measurable T cell component to vaccine-induced protection and that strengthening this would improve efficacy and duration of immunity.The project objective therefore focuses on evaluation of novel adjuvants to enhance the potency and duration of vaccine-induced immunity. A second objective is to understand the correlation of vaccine-induced protection with humoral and cellular immune responses.A selection of 8 novel adjuvants have been identified under an ongoing BBSRC grant based on the promising results in human vaccine formulations. These adjuvants have already been tested in a small number of cattle. The aim is to supplement the oil component of the adjuvant with a novel immunostimulant that stimulates TLR or related signalling pathways. The 4 most efficient adjuvants have been selected for further study in detail during 2013. Finally the most efficacious one will be tested during 2014 to measure the duration of the induced immunity.The studentship project will study in detail the humoral and cellular immune responses in the samples originating from the vaccinated and challenge cattle. Immune responses to be analysed include ex vivo IFNgamma ELISPOT, to analyse FMDV-specific IFNgamma producing effector cells, and cultured IFNgamma ELISPOT to determine the frequency of FMDV-specific, central memory T cells; FMDV-specific T-cell proliferation assays; analysis of FMDV-specific cytokine production in whole blood assays; analysis of T cells by flow cytometry and FMDV-specific B-cell ELISPOT to measure the B cell/memory B cell response.

Summary

unavailable

Committee	Not funded via Committee
Research Topics	Animal Health, Immunology, Microbiology
Research Priority	X – Research Priority information not available
Research Initiative	X - not in an Initiative
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search